lpettet / iStockphoto.com
The strongest cannabidiol (CBD) patent portfolios are owned by Roche, Boehringer Ingelheim, and AbbVie, according to a report released earlier this week.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Clarivate Analytics, patent filings, market research, cannabis innovation, cannabidiol, pain, inflammation, global patenting activity, Roche, Boehringer